Clinical Trials Logo
  1. Home
  2. Central Nervous System Neoplasms
  3. NCT02095353

Comparison of Contrast Agents for MRI Perfusion Analysis in Brain Tumor Patients

Central Nervous System Neoplasms Clinical Trial

Official title:
Gadobenate Dimeglumine Compared to Gadobutrol for MRI Perfusion Analysis in Brain Tumor Patients

Clinical Trial Summary

This study will compare the use of two contrast agents to analyze blood flow characteristics of brain tumors.

Clinical Trial Description

This study will compare contrast agents, gadobenate dimeglumine and gadobutrol, for MRI perfusion analysis in brain tumor patients. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02095353
Study type Observational
Source University of Nebraska
Contact
Status Terminated
Phase
Start date September 1, 2014
Completion date March 7, 2017
View Details
See also
  Status Clinical Trial Phase
Completed NCT00329589 - A Trial Using Velcade Plus Chemoradiation for Central Nervous System, Head and Neck, and Cervical Cancer Patients Phase 1
Completed NCT03257631 - A Study of Pomalidomide Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors Phase 2
Recruiting NCT04541082 - Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms Phase 1
Active, not recruiting NCT01180881 - Neurobehavioral Functioning in Pediatric Brain Tumor Patients After Proton Beam Radiation Treatment
Completed NCT00822432 - Coproporphyrine Isomers and Methotrexate Elimination N/A
Completed NCT02291822 - Retrospective Study of MRI in Pediatric Patients N/A
Completed NCT03750188 - Evaluation of Safety and Efficacy of ProHance in Pediatric Patients <2yrs
Completed NCT03188354 - Diagnostic Assessment of 18F-fluciclovine and 18F-FDG -PET/MRI of Primary Central Nervous System Lymphoma N/A
Completed NCT03147989 - Retrospective Study of MRI With MULTIHANCE at 0.10 and 0.05 mmol/Kg Dose in CNS Patients
Completed NCT03434262 - SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors Phase 1
Not yet recruiting NCT05850377 - 5-Aminolevulinic Acid (5-ALA) Gliolan®: Usage Increase Proposal for Neurosurgical Procedures in High-Grade Gliomas
Terminated NCT01582152 - Phase I/II Bevacizumab Versus Bevacizumab Plus TPI 287 for Recurrent Glioblastoma Phase 1/Phase 2
Active, not recruiting NCT04525014 - RRx-001 Given With Irinotecan and Temozolomide for Pediatric Patients With Recurrent or Progressive Malignant Solid and Central Nervous System Tumors Phase 1
Terminated NCT02692898 - Biomarker Analysis of Central Nervous System Tumors
Not yet recruiting NCT04671368 - Diagnostic Efficiency of Artificial Intelligence for Surgical Neuropathology N/A
Completed NCT00328458 - EPO906 Plus Radiation Therapy for the Treatment of Cancer Patients Phase 1
Recruiting NCT04859543 - Pediatric Prospective Personalized Immune and Target Identification Trial N/A
Terminated NCT04096716 - Mapping Draining Lymph Nodes in CNS Malignancies Phase 1
Completed NCT01931098 - Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab Phase 2
Recruiting NCT05386108 - Study of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/HER2- Breast Cancer Phase 1/Phase 2